Condition
Refractory Osteosarcoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
11 shownSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888 · 2021-05-03
ACTIVE_NOT_RECRUITINGTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13
ACTIVE_NOT_RECRUITINGIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)NCT04195555 · 2020-07-20
ACTIVE_NOT_RECRUITINGUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994 · 2018-11-14
ACTIVE_NOT_RECRUITINGPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250 · 2018-08-13
COMPLETEDLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasNCT03449108 · 2018-04-27
ACTIVE_NOT_RECRUITINGEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)NCT03213652 · 2018-04-17
ACTIVE_NOT_RECRUITINGTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)NCT03213665 · 2017-11-13
COMPLETEDOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)NCT03233204 · 2017-09-14
COMPLETEDLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)NCT03213704 · 2017-08-23
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGCommon interventions
Computed TomographyPROCEDURE4Magnetic Resonance ImagingPROCEDURE4Radionuclide ImagingPROCEDURE4X-Ray ImagingPROCEDURE4Biospecimen CollectionPROCEDURE3Bone Marrow Aspiration and BiopsyPROCEDURE3Bone ScanPROCEDURE3Laboratory Biomarker AnalysisOTHER3Pharmacological StudyOTHER3Positron Emission TomographyPROCEDURE3EnsartinibDRUG2IvosidenibDRUG2Larotrectinib SulfateDRUG2OlaparibDRUG2PalbociclibDRUG2SelpercatinibDRUG2TazemetostatDRUG2TipifarnibDRUG2UlixertinibDRUG2AldesleukinBIOLOGICAL1Autologous Tumor Infiltrating Lymphocytes LN-145BIOLOGICAL1Autologous Tumor Infiltrating Lymphocytes LN-145-S1BIOLOGICAL1Biopsy ProcedurePROCEDURE1CyclophosphamideDRUG1ErdafitinibDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING8
COMPLETED3
Phase mix
PHASE211
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.